一项采用欧米伽-3 多不饱和脂肪酸（OPFA ω-3）预防使用阿米替林的慢性偏头痛患者偏头痛的双盲、随机、安慰剂对照临床试验。

A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline.

机构信息

a Center of Neurology and Headache of Piauí , Teresina , Brazil.

b Botica Pharmacies , Teresina , Brazil.

出版信息

Nutr Neurosci. 2018 Apr;21(3):219-223. doi: 10.1080/1028415X.2016.1266133. Epub 2017 Jan 5.

DOI:10.1080/1028415X.2016.1266133

PMID:28056704

Abstract

OBJECTIVE

To determine the prophylactic effect of OPFAϖ-3 in migraine.

SUBJECTS AND METHODS

This was a prospective, experimental, controlled, double-blind, and with comparison groups study. Sixty patients diagnosed with chronic migraine, according to the criteria of the International Classification of Headache Disorders, Third Edition (beta version) (ICHD-3β), were prophylactically treated with amitriptyline. They were divided into two equal groups: in group 1, prophylaxis was associated with OPFAϖ-3 and in group 2 with placebo. After 60 days, both groups were assessed by a second researcher.

RESULTS

Of the 60 patients with chronic migraine, only 51 patients (15 men and 36 women) completed the treatment. The group that received OPFAϖ-3 consisted of 27 (52.9%) patients (six men and 21 women), while the control group was equal to 24 (47.1%) patients (nine men and 15 women). These differences were not significant (χ = 1.428; P = 0.375). In 66.7% (18/27) of the patients who used OPFAϖ-3, there was a reduction of more than 80.0% per month in the number of days of headache, while in the control group, the same improvement occurred in 33.3% (8/24) of patients. This difference was significant (χ = 5.649; P = 0.036).

CONCLUSIONS

Polyunsaturated omega 3 fatty acids (OPFAϖ-3) are useful for prophylaxis of migraine attacks.

摘要

目的

确定 OPFAω-3 在偏头痛中的预防作用。

对象和方法

这是一项前瞻性、实验性、对照、双盲、有对照组的研究。60 例符合国际头痛疾病分类第三版（β 版）（ICHD-3β）标准的慢性偏头痛患者接受阿米替林预防治疗。他们被分为两组：组 1 联合 OPFAω-3 预防，组 2 给予安慰剂。60 天后，由第二位研究者对两组患者进行评估。

结果

60 例慢性偏头痛患者中，仅有 51 例（15 例男性和 36 例女性）完成了治疗。接受 OPFAω-3 治疗的患者中，27 例（52.9%）为男性（6 例）和女性（21 例），而对照组为 24 例（47.1%），为男性（9 例）和女性（15 例）。这些差异无统计学意义（χ=1.428，P=0.375）。OPFAω-3 组中 66.7%（18/27）的患者头痛天数每月减少超过 80.0%，而对照组中，同样的改善发生在 33.3%（8/24）的患者中。这一差异具有统计学意义（χ=5.649，P=0.036）。